AFME Stock Overview
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Affluent Medical SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.99 |
| 52 Week High | €2.30 |
| 52 Week Low | €0.93 |
| Beta | 0.50 |
| 1 Month Change | 8.45% |
| 3 Month Change | 17.06% |
| 1 Year Change | 65.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| AFME | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 8.2% | 0.8% | -0.9% |
| 1Y | 65.8% | 14.5% | 1.9% |
Return vs Industry: AFME exceeded the French Medical Equipment industry which returned 14.5% over the past year.
Return vs Market: AFME exceeded the French Market which returned 1.9% over the past year.
Price Volatility
| AFME volatility | |
|---|---|
| AFME Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.9% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: AFME's share price has been volatile over the past 3 months.
Volatility Over Time: AFME's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 52 | Sebastien Ladet | www.affluentmedical.com |
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
Affluent Medical SA Fundamentals Summary
| AFME fundamental statistics | |
|---|---|
| Market cap | €61.49m |
| Earnings (TTM) | -€15.01m |
| Revenue (TTM) | €1.22m |
50.2x
P/S Ratio-4.1x
P/E RatioIs AFME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFME income statement (TTM) | |
|---|---|
| Revenue | €1.22m |
| Cost of Revenue | €2.23m |
| Gross Profit | -€1.01m |
| Other Expenses | €14.01m |
| Earnings | -€15.01m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | -82.27% |
| Net Profit Margin | -1,226.72% |
| Debt/Equity Ratio | 44.3% |
How did AFME perform over the long term?
See historical performance and comparison